Stock Analysis of Allarity Therapeutics Inc (ALLR) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code ALLR
Close 0.639
Change -0.0338 / 5.02 %
Volume 4325.03 K
Vol Change 1503.23 K / 53.27 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthStrong Bearish
Growth Index Poor Growth Stock
Value Index Poor Value Stock
Profitability Index Poor Profitability Stock
Stability Index Poor Stability Stock


Fundamental View of Allarity Therapeutics Inc
PE (TTM)

-2.42

Very Poor
Price / Book

-18.57

Very Poor
Price / Sales

453.18

Very Poor
Piotroski F Score

1.0

Very Poor
Market Cap

1648.24 K

Enterprise Value

2782.24 K

ROA (TTM)

-164.02

Very Poor
ROE (TTM)

0

Poor
Net Margin (TTM)

-18696.43

Very Poor
Revenue

%

0
Net Profit

18.94 %

-13017.00 K
Debt to Equity

-0.473

Very Poor
Altman Z Score

-15.83

Very Poor
Quick Ratio

0

Poor
Cash Ratio

0.0117

Poor


Highs/Lows of Allarity Therapeutics Inc
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week0.7911 19.23 % 1.54 % 0.84430.63213-May-2417-May-24
Two Week1.0 36.10 % 3.42 % 1.180.63206-May-2417-May-24
One Month1.5 57.40 % 5.60 % 3.460.63202-May-2417-May-24
Three Month8.062 92.07 % 5.95 % 8.80.63229-Feb-2417-May-24
Six Months10.402 93.86 % 17.48 % 22.00.63205-Dec-2317-May-24
One year276.0 99.77 % 27.52 % 283.20.63226-May-2317-May-24
Two year39760.0 100.00 % 29.70 % 95060.00.63224-Mar-2317-May-24


Technical View of Allarity Therapeutics Inc
RSI

14.25

Mild Bearish
MACD

-0.740

Bullish
ADX

24.43

Neutral
Super Trend

1.48

Mild Bearish
Williams %R

-99.75

Mild Bearish
CCI

-88.98

Neutral


EMA 5

0.704

Mild Bearish
EMA 15

1.00

Strong Bearish
EMA 50

3.26

Strong Bearish
EMA 100

46.12

Strong Bearish
SMA 100

6.26

Strong Bearish
SMA 200

12.75

Strong Bearish
SMA 5 / 20

0.715 / 1.04

Mild Bearish
SMA 15 / 50

0.918 / 3.46

Strong Bearish
SMA 50 / 200

3.46 / 12.75

Mild Bearish




Charts of Allarity Therapeutics Inc


Returns of Allarity Therapeutics Inc with Peers
Period / StockALLRAFIBBBLGNMRD
1 Week-19.23%43.90%-2.08%83.28%
1 Mth-57.40%-63.98%6.21%-25.00%
3 Mth-92.07%-70.20%-51.48%-31.33%
6mth-93.86%-76.02%-61.48%-77.20%
1 Year-99.77%-93.14%-95.33%-91.62%
2 Year-100.00%-93.42%-99.50%-97.86%
5 Years---99.97%-99.35%
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Allarity Therapeutics Inc with Peers
Ratio / StockALLRAFIBBBLGNMRD
PE-2.42-0.0175-0.132-0.190
P/B-18.570.0640.214-0.118
ROA-164.02-121.18-113.22-74.55
ROE0-369.40-162.020
Debt To Equity-0.473-40.090-1.70
Revenue0
% 		19658.00 K
20.14 % 		0
% 		-1476.39 K
392.99 %
Net Income-13017.00 K
18.94 % 		-32790.00 K
17.23 % 		-6505.39 K
338.19 % 		-25104.74 K
80.78 %


Technicals of Allarity Therapeutics Inc with Peers
Technical / StockALLRAFIBBBLGNMRD-
ADX24.4335.7527.5323.19
CMF-0.690-0.255-0.362-0.315
MFI77.8033.0080.3048.41
RSI14.2531.7248.8553.39
MACD Abv SignalTrueFalseTrueTrue
Price Above 50 MAFalseFalseFalseFalse-
Price Above 200 MAFalseFalseFalseFalse-


About : Allarity Therapeutics Inc

Address : 24 School Street, Boston, MA, United States, 02108
Tel : 401 426 4664
URL : https://www.allarity.com
Code : ALLR, ISIN : US0167441049, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 21_Dec_2021
Employee Count : 5

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.


Note : All Data Generated at the End of Trading Hours (EOD Data)